Massive 28,000-Person study tests which diabetes drug better prevents heart failure hospitalizations

This study analyzed real-world medical records to compare two diabetes medications, tirzepatide and semaglutide, in people with both type 2 diabetes and a specific type of heart failure. Researchers examined over 28,000 patients' insurance claims data to see which medication was more effective at preventing hospitalizations for heart failure or death from any cause. The goal was to understand if real-world data can reliably answer treatment questions when traditional clinical trials aren't practical.